Patients with peripherally located tumors will receive 48 cobalt gray equivalent over 2 weeks; patients with centrally located lung tumors will receive 60 cobalt gray equivalent over 2 to 3 weeks.
The primary outcome is grade 3 or higher toxicity; secondary outcomes include outcomes, survival, and quality of life.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT00875901.
Status: This study is open and recruiting patients as of April 14, 2017.
This study is sponsored by the University of Florida.
- Clinicaltrials.gov. Proton therapy for stage I non-small cell lung cancer (LU03) (LU03). NCT00875901. https://clinicaltrials.gov/ct2/show/NCT00875901. Accessed April 14, 2017.